Cartesian Therapeutics Stock Performance
| RNAC Stock | 6.68 0.08 1.18% |
The firm shows a Beta (market volatility) of 1.41, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cartesian Therapeutics will likely underperform. At this point, Cartesian Therapeutics has a negative expected return of -0.51%. Please make sure to confirm Cartesian Therapeutics' daily balance of power, and the relationship between the skewness and day typical price , to decide if Cartesian Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Cartesian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2026. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (1.18) | Five Day Return (7.61) | Year To Date Return (60.54) | Ten Year Return (98.41) | All Time Return (98.41) |
Last Split Factor 1:30 | Last Split Date 2024-04-05 |
1 | Acquisition by Kalayoglu Murat of 7800 shares of Cartesian Therapeutics at 16.93 subject to Rule 16b-3 | 10/17/2025 |
2 | Disposition of 5600 shares by Kurtoglu Metin of Cartesian Therapeutics at 17.2787 subject to Rule 16b-3 | 10/31/2025 |
3 | Cartesian Therapeutics GAAP EPS of -1.38 misses by 0.54, revenue of 0.45M beats by 0.27M | 11/06/2025 |
4 | Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositi... | 11/13/2025 |
5 | Cartesian Therapeutics Receives Lowered Price Target but Retains Buy Rating - GuruFocus | 11/19/2025 |
6 | Disposition of 7500 shares by Emily English of Cartesian Therapeutics at 3.3 subject to Rule 16b-3 | 11/28/2025 |
7 | Heres Why Were Watching Cartesian Therapeutics Cash Burn Situation | 12/05/2025 |
8 | Independent Director of Cartesian Therapeutics Picks Up 168 percent More Stock | 12/11/2025 |
9 | Insider Trading | 12/16/2025 |
10 | Cartesian Therapeutics, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts - MarketBeat | 12/17/2025 |
| Begin Period Cash Flow | 78.3 M | |
| Total Cashflows From Investing Activities | -8.7 M |
Cartesian | Build AI portfolio with Cartesian Stock |
Cartesian Therapeutics Relative Risk vs. Return Landscape
If you would invest 985.00 in Cartesian Therapeutics on September 28, 2025 and sell it today you would lose (317.00) from holding Cartesian Therapeutics or give up 32.18% of portfolio value over 90 days. Cartesian Therapeutics is currently does not generate positive expected returns and assumes 4.4975% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than Cartesian, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cartesian Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cartesian Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cartesian Therapeutics, and traders can use it to determine the average amount a Cartesian Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1127
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RNAC |
Based on monthly moving average Cartesian Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cartesian Therapeutics by adding Cartesian Therapeutics to a well-diversified portfolio.
Cartesian Therapeutics Fundamentals Growth
Cartesian Stock prices reflect investors' perceptions of the future prospects and financial health of Cartesian Therapeutics, and Cartesian Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cartesian Stock performance.
| Return On Equity | -70.29 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (46.61) % | ||||
| Current Valuation | 45 M | ||||
| Shares Outstanding | 26 M | ||||
| Price To Book | 31.26 X | ||||
| Price To Sales | 159.22 X | ||||
| Revenue | 38.91 M | ||||
| Gross Profit | (51.76 M) | ||||
| EBITDA | (75.99 M) | ||||
| Net Income | (77.42 M) | ||||
| Cash And Equivalents | 106.44 M | ||||
| Total Debt | 13.98 M | ||||
| Book Value Per Share | (1.38) X | ||||
| Cash Flow From Operations | (23.67 M) | ||||
| Earnings Per Share | (1.33) X | ||||
| Market Capitalization | 173.7 M | ||||
| Total Asset | 435.02 M | ||||
| Retained Earnings | (692.07 M) | ||||
| Working Capital | 193.65 M | ||||
About Cartesian Therapeutics Performance
By analyzing Cartesian Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Cartesian Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cartesian Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cartesian Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.34) | |
| Return On Capital Employed | (0.11) | (0.11) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | 11.38 | 11.95 |
Things to note about Cartesian Therapeutics performance evaluation
Checking the ongoing alerts about Cartesian Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cartesian Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cartesian Therapeutics generated a negative expected return over the last 90 days | |
| Cartesian Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 38.91 M. Net Loss for the year was (77.42 M) with loss before overhead, payroll, taxes, and interest of (51.76 M). | |
| Cartesian Therapeutics currently holds about 106.44 M in cash with (23.67 M) of positive cash flow from operations. | |
| Cartesian Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 60.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Cartesian Therapeutics, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts - MarketBeat |
- Analyzing Cartesian Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cartesian Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cartesian Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cartesian Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cartesian Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cartesian Therapeutics' stock. These opinions can provide insight into Cartesian Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cartesian Stock analysis
When running Cartesian Therapeutics' price analysis, check to measure Cartesian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cartesian Therapeutics is operating at the current time. Most of Cartesian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cartesian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cartesian Therapeutics' price. Additionally, you may evaluate how the addition of Cartesian Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |